oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital.ORCID iD: 0000-0002-7498-7157
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden.
Department of Clinical and Experimental Medicine, Division of Oncology, Linköping University, Linköping, Sweden.
Department of Clinical and Experimental Medicine, Division of Oncology, Linköping University, Linköping, Sweden.
Show others and affiliations
2013 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 29, no 4, p. 1467-1474Article in journal (Refereed) Published
Abstract [en]

Reduced or absent Wwox expression has recently been associated with tamoxifen resistance in breast cancer and has also been proposed as a candidate predictive marker for treatment. We aimed to investigate the correlation of Wwox expression with the outcome of tamoxifen treatment by examining tissues from 912 randomized breast cancer patients. Paraffin-embedded tissues from patient tumors were arranged on tissue microarray, and Wwox protein was stained using immunohistochemistry. After microscopic examination, the results were analyzed with Cox regression, Kaplan-Meier survival curves and the log-rank test. In the group of cases having a tumor absent for Wwox expression, there was no difference in recurrence-free survival between treated and untreated patients (P=0.81). For treated cases with a tumor expressing moderate or strong Wwox protein, recurrence-free survival was improved (P=0.001 and P=0.003, respectively). The test for interaction between Wwox and treatment response demonstrated a decreased risk of recurrence for treated patients with a moderate or strong Wwox expression (HR=0.31, 95% CI 0.10-0.98 and HR=0.28, 95% CI 0.08-0.97, respectively). Our results indicate that patients with high expression of Wwox may gain more benefit from treatment with tamoxifen.

Place, publisher, year, edition, pages
Athens, Greece: Spandidos Publications , 2013. Vol. 29, no 4, p. 1467-1474
Keywords [en]
Wwox, breast cancer, tamoxifen, randomized patients
National Category
Cancer and Oncology
Research subject
Biomedicine
Identifiers
URN: urn:nbn:se:oru:diva-41720DOI: 10.3892/or.2013.2261ISI: 000316510600028PubMedID: 23381945Scopus ID: 2-s2.0-84874702740OAI: oai:DiVA.org:oru-41720DiVA, id: diva2:781019
Available from: 2015-01-15 Created: 2015-01-15 Last updated: 2018-05-23Bibliographically approved
In thesis
1. Biological profiles of endocrine breast cancer
Open this publication in new window or tab >>Biological profiles of endocrine breast cancer
2015 (English)Doctoral thesis, comprehensive summary (Other academic)
Place, publisher, year, edition, pages
Örebro: Örebro university, 2015. p. 82
Series
Örebro Studies in Medicine, ISSN 1652-4063 ; 123
Keywords
Endocrine breast cancer, tamoxifen, Foxl2, Wwox, ErbB4, HER4, gene expression, randomized patients
National Category
Cancer and Oncology
Research subject
Biomedicine
Identifiers
urn:nbn:se:oru:diva-43963 (URN)978-91-7529-071-3 (ISBN)
Public defence
2015-05-29, Universitetssjukhuset, Wilandersalen, Södra Grev Rosengatan, Örebro, 09:00 (Swedish)
Opponent
Supervisors
Funder
Swedish Cancer SocietyCancer and Allergy Foundation
Note

Funding: Magnus Bergvall Cancer Foundation; Percy Falk foundation for research in breast and prostate cancer; Nyckelfonden; Örebro University Hospital; Lions cancer research foundation, Region Uppsala-Örebro

Available from: 2015-03-30 Created: 2015-03-30 Last updated: 2017-10-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Göthlin Eremo, AnnaWegman, PiaWingren, Sten

Search in DiVA

By author/editor
Göthlin Eremo, AnnaWegman, PiaWingren, Sten
By organisation
School of Health and Medical Sciences, Örebro University, SwedenÖrebro University Hospital
In the same journal
Oncology Reports
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 281 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf